Ingevity Balansräkning Hälsa
Finansiell hälsa kriterier kontrolleras 3/6
Ingevity har ett totalt eget kapital på $38.9M och en total skuld på $1.1B vilket ger sin skuldsättningsgrad till 2842.9%. Dess totala tillgångar och totala skulder är $1.7B respektive $1.6B. Ingevity s EBIT är $267.8M vilket gör dess räntetäckningsgrad 3.9. Den har kontanter och kortsiktiga investeringar på $95.4M.
Viktig information
2,842.93%
Skuldsättning i förhållande till eget kapital
US$1.11b
Skuld
| Räntetäckningsgrad | 3.9x |
| Kontanter | US$95.40m |
| Eget kapital | US$38.90m |
| Summa skulder | US$1.61b |
| Totala tillgångar | US$1.65b |
Nya uppdateringar om finansiell hälsa
Analysartikel • Sep 06
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Feb 20
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysartikel • Oct 13
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Jul 13
Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Mar 22
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Recent updates
Seeking Alpha • May 19
Ingevity - Shrinking To Grow
Summary Ingevity is pursuing a shrink-to-grow strategy, divesting non-core assets to boost focus and margins. Recent asset sales fetched modest prices, following significant impairment charges, but have not materially impacted earnings. Ingevity´s leverage is gradually declining, with 2026 guidance targeting $4.70–$5.20 EPS and $370–$395 million adjusted EBITDA. I remain cautiously optimistic, seeing potential for re-rating if further simplification or a performance materials spin-off occurs. Read the full article on Seeking Alpha
Uppdatering av berättelse • May 14
NGVT: Future P/E Will Reward Margin Strength Despite Recent Impairment Charge
Analysts have raised Ingevity's price target from $80.50 to $85.50, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe more accurately reflect the stock's risk and earnings profile. What's in the News Ingevity reaffirmed earnings guidance for full year 2026, with expected net sales in a range of $1.05b to $1.15b (company guidance).Uppdatering av berättelse • Apr 28
NGVT: Future P/E Will Reflect Margin Resilience And Impairment Charge Impact
Analysts have increased their price target for Ingevity to $80.50 from $79.25, citing updated assumptions on long term revenue growth, profit margin resilience, and future P/E levels reflected in recent research, including the Wells Fargo target increase. Analyst Commentary Recent research behind the new US$80.50 price target focuses on refreshed assumptions for long term revenue trends, margin resilience, and the P/E level that investors may be willing to ascribe to Ingevity over time.Uppdatering av berättelse • Apr 11
NGVT: Future P/E Will Depend On Margin Execution And Impairment Fallout
Analysts have raised their price target on Ingevity by $5 to $79.25, citing updated assumptions regarding discount rates, long-term revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts raising the price target to $79.25 are updating their models to reflect changes in discount rates, long term revenue assumptions, profit margins, and future P/E expectations.Uppdatering av berättelse • Mar 28
NGVT: Higher P/E Will Rely On Future Margin Delivery
Analysts have lifted their price target on Ingevity by $5 to $79.25, citing updated assumptions on discount rates, long term revenue growth, profit margins, and future P/E, which support a slightly higher valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as consistent with updated assumptions on discount rates and long term revenue growth, which they believe better reflect the company’s current risk profile and earnings potential.Uppdatering av berättelse • Mar 13
NGVT: Higher P/E Outlook Will Depend On Margin Execution
Analysts have raised their price target on Ingevity by $8.50 to $79.25, citing updated views on revenue growth, profit margins, and an expected higher future P/E multiple. Analyst Commentary Recent Street research has focused on how Ingevity might justify a higher valuation, with specific attention on revenue trends, profitability, and the potential for the shares to support a richer P/E multiple over time.Uppdatering av berättelse • Feb 24
NGVT: Updated P/E Assumptions And Buybacks Will Shape Balanced Outlook
Analysts have raised their price target on Ingevity by $5 to $70.75, citing updated assumptions around discount rates and future P/E as the main factors behind this revised view. Analyst Commentary Analysts framing the new US$70.75 price target are focusing less on short term headlines and more on what updated discount rate and P/E assumptions imply for Ingevity's risk profile and execution needs.Uppdatering av berättelse • Feb 09
NGVT: Share Repurchases And Battery Materials License Will Guide Balanced Outlook
Analysts have raised their price target on Ingevity from US$69.50 to US$70.75, citing updated assumptions around discount rates, revenue trends, profit margins and future P/E expectations. Analyst Commentary Analysts who support the higher price target describe it as a fine tuning of their models rather than a wholesale rethink.Uppdatering av berättelse • Jan 26
NGVT: Buybacks And Battery Materials License Will Shape Balanced Outlook
Analysts have maintained their fair value estimate for Ingevity at US$69.50, with only minor adjustments to inputs such as the discount rate and long-term P/E assumptions. These changes reflect updated modeling rather than a change in conviction.Uppdatering av berättelse • Jan 10
NGVT: Battery Additives And Buybacks Will Shape Balanced Long-Term Outlook
Analysts have adjusted their price target on Ingevity to US$69.50. This reflects updated views on the discount rate, revenue outlook, profit margins and future P/E assumptions.Uppdatering av berättelse • Dec 25
NGVT: Future Battery Materials Role Will Drive Long-Term Upside Despite Margin Reset
Analysts have modestly raised their price target on Ingevity by about $1.25 to approximately $69.50. They cite a lower perceived discount rate and an improving revenue trajectory, which more than offset concerns about a structurally lower profit margin and a higher future valuation multiple.Uppdatering av berättelse • Dec 10
NGVT: Future Battery Materials Role Will Drive Stronger Long Term Upside Potential
Analysts have nudged their price target on Ingevity higher from $65.25 to $68.25, citing a modestly richer future earnings multiple that more than offsets slightly softer revenue growth and margin assumptions. What's in the News Ingevity announced that Executive Vice President and Chief Financial Officer Mary Dean Hall will transition from her role effective May 1, 2026, and remain in an advisory capacity for one year, as part of a planned leadership change.Analysartikel • Sep 30
Is There Now An Opportunity In Ingevity Corporation (NYSE:NGVT)?
While Ingevity Corporation ( NYSE:NGVT ) might not have the largest market cap around , it received a lot of attention...Analysartikel • Sep 06
Does Ingevity (NYSE:NGVT) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Uppdatering av berättelse • Sep 05
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook. Analyst Commentary Q2 earnings beat, demonstrating stronger-than-expected financial performance.Uppdatering av berättelse • Aug 06
Portfolio Repositioning And Engineered Additives Will Create A Sustainable Future
The upward revision in Ingevity's revenue growth forecasts from 2.6% to 3.7% per annum has outweighed the impact of a higher discount rate, resulting in an increased consensus analyst price target from $54.25 to $57.00. What's in the News Ingevity Corporation maintained its earnings guidance for 2025, expecting sales between $1.25 billion and $1.40 billion.Analysartikel • Jun 27
Ingevity Corporation (NYSE:NGVT) Shares Could Be 39% Below Their Intrinsic Value Estimate
Key Insights The projected fair value for Ingevity is US$71.30 based on 2 Stage Free Cash Flow to Equity Ingevity's...Analysartikel • May 28
Subdued Growth No Barrier To Ingevity Corporation (NYSE:NGVT) With Shares Advancing 33%
Those holding Ingevity Corporation ( NYSE:NGVT ) shares would be relieved that the share price has rebounded 33% in the...Ny berättelse • May 27
Premium Markets Will Secure Long Term Value
Expansion into premium specialty chemicals and advanced materials is increasing margins and positioning for growth as sustainability trends and vehicle electrification accelerate.Analysartikel • Apr 05
Why We're Not Concerned Yet About Ingevity Corporation's (NYSE:NGVT) 32% Share Price Plunge
Ingevity Corporation ( NYSE:NGVT ) shares have had a horrible month, losing 32% after a relatively good period...Analysartikel • Feb 20
Ingevity (NYSE:NGVT) Has A Somewhat Strained Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysartikel • Jan 16
Ingevity Corporation (NYSE:NGVT) Shares Could Be 49% Below Their Intrinsic Value Estimate
Key Insights Ingevity's estimated fair value is US$82.84 based on 2 Stage Free Cash Flow to Equity Ingevity is...Analysartikel • Nov 07
What Ingevity Corporation's (NYSE:NGVT) 32% Share Price Gain Is Not Telling You
Ingevity Corporation ( NYSE:NGVT ) shareholders have had their patience rewarded with a 32% share price jump in the...Analysartikel • Oct 13
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Sep 08
Ingevity Corporation's (NYSE:NGVT) Prospects Need A Boost To Lift Shares
When you see that almost half of the companies in the Chemicals industry in the United States have price-to-sales...Seeking Alpha • Aug 27
Ingevity: The Risk-Reward Ratio Is Still Unfavorable
Summary Ingevity, once considered a growth story, turned out to be a classic example of market cycles. While Road Technology and Performance Materials performed reasonably well in the first half of 2024, the Industrial Specialties segment dragged down revenue and net income. Given the company's significant debt burden, risk-averse investors should seek safer options within the chemical industry. Read the full article on Seeking AlphaAnalysartikel • Aug 03
Ingevity Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
There's been a notable change in appetite for Ingevity Corporation ( NYSE:NGVT ) shares in the week since its quarterly...Analysartikel • Jul 13
Ingevity (NYSE:NGVT) Use Of Debt Could Be Considered Risky
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Jun 14
Should You Investigate Ingevity Corporation (NYSE:NGVT) At US$45.90?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it received a lot of attention from a...Analysartikel • Apr 18
Are Investors Undervaluing Ingevity Corporation (NYSE:NGVT) By 44%?
Key Insights Ingevity's estimated fair value is US$78.59 based on 2 Stage Free Cash Flow to Equity Current share price...Analysartikel • Mar 22
Is Ingevity (NYSE:NGVT) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Jan 23
What Is Ingevity Corporation's (NYSE:NGVT) Share Price Doing?
Ingevity Corporation ( NYSE:NGVT ), might not be a large cap stock, but it saw a double-digit share price rise of over...Analysartikel • Jan 04
Ingevity Corporation (NYSE:NGVT) Doing What It Can To Lift Shares
With a price-to-earnings (or "P/E") ratio of 12.6x Ingevity Corporation ( NYSE:NGVT ) may be sending bullish signals at...Analysartikel • Nov 10
These Analysts Just Made An Incredible Downgrade To Their Ingevity Corporation (NYSE:NGVT) EPS Forecasts
The latest analyst coverage could presage a bad day for Ingevity Corporation ( NYSE:NGVT ), with the analysts making...Analys av finansiell ställning
Kortfristiga skulder: NGVT s kortfristiga tillgångar ( $581.8M ) överstiger dess kortfristiga skulder ( $409.4M ).
Långfristiga skulder: NGVT s kortfristiga tillgångar ( $581.8M ) täcker inte dess långfristiga skulder ( $1.2B ).
Skuld till eget kapital Historik och analys
Skuldnivå: NGVT s nettoskuld i förhållande till eget kapital ( 2597.7% ) anses vara hög.
Minska skulden: NGVT s skuldsättningsgrad har ökat från 179.9% till 2842.9% under de senaste 5 åren.
Skuldtäckning: NGVT s skuld är väl täckt av operativt kassaflöde ( 27.5% ).
Räntetäckning: NGVT s räntebetalningar på sin skuld är väl täckta av EBIT ( 3.9 x täckning).
Balansräkning
Upptäck friska företag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 07:06 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Ingevity Corporation bevakas av 8 analytiker. 4 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Paretosh Misra | Berenberg |
| John McNulty | BMO Capital Markets Equity Research |
| Jonathan Tanwanteng | CJS Securities, Inc. |